BioPharma Resources

Drug Trial Radar · NCT03447704

International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis

An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing Spondylitis

Last checked: Nov 19, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 228 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

228

Actual

Start

Feb 9, 2018

Primary completion

Dec 24, 2018

Study completion Mar 31, 2022

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Feb 27, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

BCD-085-5 is an International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-5 trial patients with active ankylosing spondylitis will receive 120 mg of BCD-085 subcutaneously every other week or placebo up to Week 16. Starting from week 16 all patients will receive BCD-085. Efficacy, PK and safety parameters will be evaluated.

Conditions

  • Ankylosing Spondylitis

Interventions

  • BCD-085Drug

    120 mg of BCD-085 subcutaneously at week 0,1 and 2 every other week

  • placeboOther

    2 ml of placebo subcutaneously at week 0,1 2 and every other week, starting from week 16 - 120 mg of BCD-085 subcutaneously at week 16,17 and 18 every other week

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ASAS40 rate at Week 16Time frame: Week 16

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Non-governmental Healthcare Institution "Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways"

    Chelyabinsk, Russia

  • Chelyabinsk Regional Clinical hospital

    Chelyabinsk, Russia

  • Kazan State Medical University

    Kazan', Russia

  • State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University

    Moscow, Russia

  • Omsk Regional Clinical Hospital

    Omsk, Russia

  • LLC BioEk

    Saint Petersburg, Russia

  • North-Western State Medical University n.a. I.I.Mechnikov

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.